Palvella Therapeutics, Inc. (FRA:PI6)
Germany · Delayed Price · Currency is EUR 85.50
0.00 (0.00%)
At close: Nov 28, 2025
Palvella Therapeutics Company Description
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.
The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania
Palvella Therapeutics, Inc.
| Country | United States |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 14 |
| CEO | Wesley Kaupinen |
Contact Details
Address: 125 Strafford Avenue Wayne, Nevada 19087 United States | |
| Phone | 484 253 1461 |
| Website | palvellatx.com |
Stock Details
| Ticker Symbol | PI6 |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Wesley Kaupinen | Chief Executive Officer |
| Matthew Korenberg | Chief Financial Officer |
| Kathleen Goin | Chief Operating Officer |